Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics - 10/06/15
, Caterina Di Sano a, Maria Ferraro a, Andreina Bruno a, Valentina Caputo b, Salvatore Gallina c, Mark Gjomarkaj aAbstract |
Background |
Reduced innate immunity responses as well as reduced T regulatory activities characterise bronchial asthma.
Objectives |
In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory lymphocyte sub-population was assessed.
Methods |
TLR4 and TLR2 expression in total peripheral blood mononuclear cells (PBMC), in CD4+/CD25+ and in CD4+/CD25− was evaluated, by flow cytometric analysis, in mild intermittent asthmatics (n = 14) and in controls (n = 11). The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-α selected by a multiplex assay) in asthmatics were also explored.
Results |
TLR4 and TLR2 were reduced in total PBMC from asthmatics in comparison to PBMC from controls. CD4+CD25+ cells expressed at higher extent TLR2 and TLR4 in comparison to CD4+CD25− cells. Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4+/CD25highly+ cells from asthmatics. TLR4 ligand, LPS induced Foxp3 expression. Budesonide was also able to reduce the release of IL-6 and TNF-α by PBMC of asthmatics.
Conclusions |
Budesonide potentiates the activity of Treg by increasing TLR4, TLR2 and IL-10 expression. This event is associated to the decreased release of IL-6 and TNF-α in PBMC treated with budesonide. These findings shed light on new mechanisms by which corticosteroids, drugs widely used for the clinical management of bronchial asthma, control T lymphocyte activation.
Le texte complet de cet article est disponible en PDF.Keywords : Corticosteroids, T lymphocytes, Immunoregulation, TLR
Abbreviations : BUD, FEV1, TLR, Treg, LPS, LPT
Plan
Vol 32
P. 93-100 - juin 2015 Retour au numéro
Article précédent
- The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease
- Kai-Michael Beeh, Jan Westerman, Anne-Marie Kirsten, Jacques Hébert, Lars Grönke, Alan Hamilton, Kay Tetzlaff, Eric Derom
- The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D
- Huib A.M. Kerstjens, Gaëtan Deslée, Ronald Dahl, James F. Donohue, David Young, David Lawrence, Oliver Kornmann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?